S1PR1 and multiple sclerosis: Ample evidence of S1P’s role has been collected in experiments using mice with genetic loss of S1PR1 [157,158] as well as in models that have downregulation of S1PR1 by using a functional antagonist of S1PR1, FTY720, which is an FDA-approved drug for treatment of multiple sclerosis [159].